Navigation Links
Many HIV Patients Carry Strain With Drug-Resistant Mutation
Date:2/28/2011

MONDAY, Feb. 28 (HealthDay News) -- A new study estimates that between 10 percent and 15 percent of HIV patients in Europe and the United States are infected with a form of HIV that already has at least one drug-resistant mutation.

The researchers found that the risk of treatment failure in these patients is three times higher than normal, and said their findings confirm the need for drug resistance testing in new patients to determine which antiretroviral drugs are most likely to be successful.

For the study, 10,056 HIV patients who were beginning combination antiretroviral therapy (cART) for the first time were categorized into three resistance categories: 90.5 percent (9,102 patients) had no transmitted drug-resistance (TDR); 4.7 percent (475 patients) had at least one mutation and were receiving fully active cART; 4.8 percent (479 patients) had at least one mutation and were resistant to at least one prescribed drug.

Compared to patients without TDR, those with TDR and resistance to at least one prescribed drug were more than three times as likely to experience treatment failure, confirming "the need for at least three fully active antiretroviral drugs to optimize the virological response to a first-line regimen," the researchers wrote.

But the risk of treatment failure was not significantly different between patients without TDR and those with TDR taking a fully active cART regimen containing drugs not compromised by resistance.

The researchers also found that treatment failure was higher among patients with TDR who were taking two nucleotide reverse transcriptase inhibitors (NRTIs) plus one non-nucleotide reverse transcriptase inhibitor (NNRTI) and were predicted to be on a fully active treatment, compared to patients on protease inhibitor-based regimens whose risk of treatment failure was similar to patients with no TDR.

"If drug-resistant mutations are detected before treatment initiation, a ritonavir-boosted protease inhibitor can be included in the first treatment regimen, which, because of its higher genetic barrier, could better protect from the risk of virological failure than could NNRTI," Dr. Linda Wittkop, of INSERM, University Bordeaux Segalen in Bordeaux, France, and colleagues wrote.

"These findings confirm present treatment guidelines for HIV, which state that the initial treatment choice should be based on resistance testing in treatment-naive patients," they concluded.

The study is published in the Feb. 28 online edition of The Lancet Infectious Diseases.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about HIV treatment.

-- Robert Preidt

SOURCE: The Lancet Infectious Diseases, news release, Feb. 27, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Doctors Can Influence Patients to Lose Weight: Studies
2. Heart Patients With Depression Often Find ER Delays
3. Experts call for greater pain assessment in hospitals as 65 percent of patients report problems
4. Fish Oil Seems to Help Cancer Patients Preserve Muscle
5. Standard Exams Might Not Catch Full Potential of Brain Damaged Patients
6. New way to identify patients at risk of dysphagia after head and neck cancer treatment
7. Type 1 Diabetes Patients Need New Kidney Therapies: Study
8. Many Dialysis Patients at Risk for High Radiation Exposure
9. Statins Might Help HIV Patients, Study Suggests
10. Most locked-in syndrome patients say they are happy
11. Lack of health insurance limits hepatitis C patients access to latest antiviral therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Many HIV Patients Carry Strain With Drug-Resistant Mutation
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
Breaking Medicine Technology: